Targets And Emerging Therapies For Schizophrenia

New and emerging directions in pharmaceutical research to better treat schizophrenia Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined. With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia: Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.

A broad and in-depth discussion of the important, but still uninformed, field of behavioral disturbances associated with Parkinson's disease.

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

The Neurobiology of Schizophrenia begins with an overview of the various facets and levels of schizophrenia pathophysiology, ranging systematically from its genetic basis over changes in neurochemistry and electrophysiology to a systemic neural circuits level. When possible, the editors point out connections between the various systems. The editors also depict methods and research strategies used in the respective field. The individual backgrounds of the two editors promote a synthesis between basic neuroscience and clinical relevance. Provides a comprehensive overview of neurobiological aspects of schizophrenia Discusses schizophrenia at behavioral, cognitive, clinical, electrophysiological, molecular, and genetic levels Edited by a translational researcher and a psychiatrist to promote synthesis between basic neuroscience and clinical relevance Elucidates connections between the various systems depicted, when possible

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

We are on the verge of a crisis in mental health. Over the next 30 years the number of chronically mentally ill people 55 years of age and older will double. With multiple disorders relating to mental illness and old age, these people will require unique services from a health care system that is ill prepared to deliver them. Schizophrenia Into Later Life: Treatment, Research, and Policy is the first major multidisciplinary reference on this important topic -- a landmark work for researchers, service providers, and policy makers. Broad in scope, it discusses the demographic and clinical characteristics of older schizophrenic persons, details treatment approaches, suggests research strategies, and covers the relevant economic and health policy issues. The most up-to-date, comprehensive source of information on this understudied group. It will help community psychiatrists, gerontologists, psychologists, policy makers, and social scientists meet a growing demand for services. A multidisciplinary approach with contributing experts from fields of biological psychiatry, social psychiatry, sociology, anthropology, social work, psychology, and neuropsychology will help professionals integrate services for the best outcome. A primary resource on the subject -- sections include epidemiology, biological aspects, psychosocial features, clinical care, and public policy. Today there is a distressing lack of age-appropriate clinical, rehabilitative, or residential programs for older patients with chronic mental illness. Schizophrenia in Later Life: Treatment, Research, and Policy will guide researchers, service providers, and policy makers in creating innovative new programs to help this underserved and growing population.

This crucial new work draws on empirical findings from rural North India in relation to madness and subjectivity, revealing the different structures of subjectivity underlying the narratives of schizophrenia, spirits, ghosts, and deities. Unravelling the loose ends of madness, the author explores the cultural differences in understanding and experiencing madness to examine how modern insanity is treated as a clinical disorder, but historically it represents how we form knowledge and understand self-knowledge. The author begins by theoretically investigating how the schizophrenic personifies the fractures in modern Western thought to explain why, despite decades of intense contention, the category of schizophrenia is still alive. She then examines the narratives of people in the Himalayan Mountains of rural India to reveal the discursive conditions that animate their stories around what psychology calls psychosis, critiquing the monoculturalism in trauma theory and challenging the ongoing march of the Global Mental Health Movement in the Global South. Examining what a study of madness reveals about two different cultures, and their ways of thinking and being, this is fascinating reading for students interested in mental health, critical psychology, and Indian culture.

These guidelines from NICE set out clear recommendations, based on the best available evidence, for health care professionals on how to work with and implement physical, psychological and service-level interventions for people with various mental health conditions.The book contains the full guidelines that cannot be obtained in print anywhere else. It brings together all of the evidence that led to the recommendations made, detailed explanations of the methodology behind their preparation, plus an overview of the condition covering detection, diagnosis and assessment, and the full range of treatment and care approaches. There is a worse prognosis for psychosis and schizophrenia when onset is in childhood or adolescence, and this new NICE guideline puts much-needed emphasis on early recognition and assessment of possible psychotic symptoms. For the one-third of children and young people who go on to experience severe impairment as a result of psychosis or schizophrenia the guideline also offers comprehensive advice from assessment and treatment of the first episode through to promoting recovery.This guideline reviews the evidence for recognition and management of psychosis and schizophrenia in children and young people across the care pathway, encompassing access to and delivery of services, experience of care, recognition and management of at-risk mental states, psychological and pharmacological interventions, and improving cognition and enhancing engagement with education and employment.